Insider Selling: Collegium Pharmaceutical, Inc. (NASDAQ:COLL) EVP Sells 27,500 Shares of Stock

Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) EVP Shirley R. Kuhlmann sold 27,500 shares of Collegium Pharmaceutical stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $33.04, for a total transaction of $908,600.00. Following the completion of the sale, the executive vice president now directly owns 119,184 shares of the company's stock, valued at $3,937,839.36. The trade was a 18.75 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Collegium Pharmaceutical Stock Performance

Shares of COLL traded down $0.61 during midday trading on Tuesday, hitting $33.18. 318,756 shares of the stock traded hands, compared to its average volume of 555,094. The business's 50 day moving average price is $30.57 and its two-hundred day moving average price is $34.10. The firm has a market capitalization of $1.07 billion, a PE ratio of 14.30 and a beta of 0.82. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. Collegium Pharmaceutical, Inc. has a 1-year low of $28.39 and a 1-year high of $42.29.

Institutional Trading of Collegium Pharmaceutical

Hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC lifted its stake in shares of Collegium Pharmaceutical by 124.5% in the 3rd quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company's stock worth $55,000 after acquiring an additional 792 shares during the period. CWM LLC raised its holdings in Collegium Pharmaceutical by 97.5% during the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company's stock worth $58,000 after purchasing an additional 736 shares in the last quarter. TD Private Client Wealth LLC lifted its position in Collegium Pharmaceutical by 39.5% in the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company's stock worth $66,000 after purchasing an additional 483 shares during the period. Virtus Fund Advisers LLC bought a new position in Collegium Pharmaceutical during the 3rd quarter valued at $72,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Collegium Pharmaceutical by 61.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 6,196 shares of the specialty pharmaceutical company's stock valued at $239,000 after purchasing an additional 2,352 shares in the last quarter.

Analyst Ratings Changes

A number of analysts have recently commented on the company. HC Wainwright restated a "buy" rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a report on Friday. Needham & Company LLC raised shares of Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 price target for the company in a research report on Friday. Piper Sandler reissued a "neutral" rating and issued a $37.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. Finally, StockNews.com downgraded Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, October 23rd. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $43.80.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.